1. Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD. (August 2022) Authors: Strassman, Andrew M; Melo-Carrillo, Agustin; Houle, Timothy T; Adams, Aubrey; Brin, Mitchell F; Burstein, Rami Journal: Cephalalgia Issue: Volume 42:Number 9(2022) Page Start: 933 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. (October 2019) Authors: Melo-Carrillo, Agustin; Strassman, Andrew M; Schain, Aaron J; Noseda, Rodrigo; Ashina, Sait; Adams, Aubrey; Brin, Mitchell F; Burstein, Rami Journal: Cephalalgia Issue: Volume 39:Number 11(2019) Page Start: 1358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pregnancy outcomes following exposure to onabotulinumtoxinA update: 29 years of safety observation. (January 2021) Authors: Brin, Mitchell F.; Kirby, Russell S.; Slavotinek, Anne; Adams, Aubrey; Parker, Lori; Ukah, Ahunna; Radulian, Lavinia; Yedigarova, Larisa; Yushmanova, Irina Journal: Toxicon Issue: Volume 190(2021)supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. (July 2022) Authors: Mechtler, Laszlo; Saikali, Nicolas; McVige, Jennifer; Hughes, Olivia; Traut, Alexandra; Adams, Aubrey Journal: Toxicon Issue: Volume 214(2022)Supplement 1 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗